{"id":5852,"date":"2023-03-08T14:46:00","date_gmt":"2023-03-08T14:46:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=5852"},"modified":"2025-01-15T03:04:55","modified_gmt":"2025-01-15T03:04:55","slug":"cost-effectiveness-and-economic-investment-to-eliminate-chronic-hepatitis-c-in-mexico","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/cost-effectiveness-and-economic-investment-to-eliminate-chronic-hepatitis-c-in-mexico\/","title":{"rendered":"Rentabilit\u00e9 et investissement \u00e9conomique pour \u00e9liminer l&#039;h\u00e9patite C chronique au Mexique"},"content":{"rendered":"<h2 class=\"wp-block-heading\" id=\"summary\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<p>En juillet 2020, le gouvernement mexicain a lanc\u00e9 le Programme national d&#039;\u00e9limination de l&#039;h\u00e9patite C (VHC) dans le cadre d&#039;un accord d&#039;approvisionnement, garantissant un acc\u00e8s universel et gratuit au d\u00e9pistage, au diagnostic et au traitement du VHC pour 2020-2022. Cette analyse quantifie le fardeau clinique et \u00e9conomique du VHC (MXN) dans le cadre d&#039;une poursuite (ou d&#039;une fin) de l&#039;accord. Une mod\u00e9lisation et une approche Delphi ont \u00e9t\u00e9 utilis\u00e9es pour \u00e9valuer la charge de morbidit\u00e9 (2020-2030) et l&#039;impact \u00e9conomique (2020-2035) de la base historique par rapport \u00e0 l&#039;\u00e9limination, en supposant que l&#039;accord se poursuive (\u00c9limination\u2014Accord jusqu&#039;en 2035) ou prend fin (\u00c9limination\u2014Accord \u00e0 2022). Nous avons estim\u00e9 les co\u00fbts cumul\u00e9s et les d\u00e9penses de traitement par patient n\u00e9cessaires pour atteindre un co\u00fbt net nul (la diff\u00e9rence des co\u00fbts cumul\u00e9s entre le sc\u00e9nario et la base). L&#039;\u00e9limination est d\u00e9finie comme une r\u00e9duction de 90% des nouvelles infections, de la couverture des diagnostics 90%, de la couverture des traitements 80% et de la r\u00e9duction de la mortalit\u00e9 65% d&#039;ici 2030. Une pr\u00e9valence vir\u00e9mique de 0,55% (0,50-0,60) a \u00e9t\u00e9 estim\u00e9e au 1er janvier 2021, correspondant \u00e0 745 000 (IC 95% 677 000 \u00e0 812 000) infections vir\u00e9miques au Mexique. L&#039;accord d&#039;\u00e9limination jusqu&#039;en 2035 permettrait d&#039;atteindre un co\u00fbt net nul d&#039;ici 2023 et d&#039;accumuler 31,2 milliards de dollars en co\u00fbts cumul\u00e9s. Les co\u00fbts cumul\u00e9s dans le cadre de l&#039;accord d&#039;\u00e9limination jusqu&#039;en 2022 sont estim\u00e9s \u00e0 74,2 milliards. En vertu de l&#039;\u00c9limination\u2014Accord jusqu&#039;en 2022, le prix du traitement par patient doit baisser \u00e0 11 000 pour atteindre un co\u00fbt net nul d&#039;ici 2035. Le gouvernement mexicain pourrait prolonger l&#039;accord jusqu&#039;en 2035 ou r\u00e9duire le co\u00fbt du traitement du VHC \u00e0 11 000 pour parvenir \u00e0 l&#039;\u00e9limination du VHC au net. -co\u00fbt z\u00e9ro.<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/cdafound.org\/wp-content\/uploads\/2023\/06\/Mooneyhan-2023-Cost-effectiveness-and-economic-investment-to-eliminate-CHC-in-Mexico.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary In July 2020, the Mexican Government initiated the National Program for Elimination of Hepatitis C (HCV) under a procurement agreement, securing universal, free access to HCV screening, diagnosis and treatment for 2020\u20132022. This analysis quantifies the clinical and economic burden of HCV (MXN) under a continuation (or end) to the agreement. A modelling and [&hellip;]<\/p>\n","protected":false},"author":939,"featured_media":3193,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[32,10,12],"publication-author":[128,126,130,90,97,92,127,129],"class_list":["post-5852","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-economic-impact","tag-hcv","tag-modelling","publication-author-alethse-de-la-torre-rosas","publication-author-daniel-bernal-serrano","publication-author-david-kershenobich","publication-author-ellen-mooneyhan","publication-author-homie-razavi","publication-author-ivane-gamkrelidze","publication-author-leandro-sereno","publication-author-maria-jesus-sanchez"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/939"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=5852"}],"version-history":[{"count":4,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5852\/revisions"}],"predecessor-version":[{"id":7518,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5852\/revisions\/7518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3193"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=5852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=5852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=5852"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=5852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}